Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

61.31USD
2:07am IST
Change (% chg)

$-0.56 (-0.90%)
Prev Close
$61.87
Open
$61.56
Day's High
$61.89
Day's Low
$61.00
Volume
735,186
Avg. Vol
1,537,666
52-wk High
$66.09
52-wk Low
$46.01

Select another date:

BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration

* Bristol-Myers Squibb and Syngene International expand ongoing research collaboration

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​ Source text: http://bit.ly/2iT2tvz Further company coverage:

BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study

* Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

BRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels

* Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC

* Opdivo (nivolumab) demonstrates superior three-year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC)

BRIEF-EMA validates Bristol-Myers' type II variation application for Opdivo for treatment of patients with resected high-risk advanced melanoma

* European Medicines Agency validates Bristol-Myers Squibb's type II variation application for Opdivo (nivolumab) for treatment of patients with resected high-risk advanced melanoma

UPDATE 1-Bristol-Myers sales in line, but profit margins worsen

Oct 26 Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations, but earnings fell short due to higher costs and an inventory write-off, sending shares down 4 percent.

Select another date: